EUCTR2007-005051-42-CZ进行中（未招募）不适用
A randomized study of the efficacy and safety of OncoGel™ treatment as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation prior to surgery in subjects with localized or loco-regional esophageal cancer
Protherics Salt Lake City, Inc0 个研究点目标入组 156 人开始时间: 2008年2月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 156
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Disease criteria: Subject’s esophageal cancer must meet all of the following:
- •a) Confirmation: Histologically or cytologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction. Biopsy or cytology of the primary tumor or of involved regional lymph nodes is acceptable.
- •b) Stage: Tumors must be TNM stage T2-T3, N any, M0 (no evidence of disseminated cancer except regional node involvement which may be designated as M1a”) as determined by endoscopic ultrasound.
- •c) Disease extent: Disease must be limited to the esophagus or the gastroesophageal junction, including:
- •i)Tumor does not extend more than 2 cm into the stomach
- •ii)Tumor does not extend into proximal one-third of the esophagus (Note: Bronchoscopy is required if tumor is <26 cm from the incisors or at or above the carina)
- •iii)No tracheal-esophageal fistulas present
- •iv) No apparent direct invasion by the tumor into the mucosa of the trachea or major bronchus as determined by bronchoscopy or other method.
- •v) No vascular invasion or involvement by the tumor
- •d) No evidence of metastatic disease: disease must be localized to the esophagus, including
- •i) no malignant cytology of the pleura, pericardium or peritoneum
- •ii) no radiographic evidence of distant organ involvement including lung, liver or bone (Note: any imaging study suspicious of liver metastases must be followed up with a negative biopsy prior to enrolling subject in the study)
- •2) Medically able to tolerate major abdominal and/or thoracic surgery
- •3) Able to undergo EUS procedure and pass EUS probe through esophageal lumen
- •4) Able to receive concurrent systemic chemotherapy (cisplatin and 5-FU) and RT
- •5) Clinical management plan includes esophagectomy after completion of two courses of CRT
- •6) Karnofsky Performance Status of =60 (refer to Section 13.2 for details)
- •7) Minimum life expectancy of 4 months as determined by the Investigator
- •8) Adequate hematologic function, defined as
- •a) Absolute neutrophil count (ANC) =1500/mm3
- •b) Platelet count =100,000/mm3
- •c) Hemoglobin =9 g/dL
- •9) Adequate hepatic function, defined as
- •a) Total bilirubin <1.5 X upper limit of normal (ULN)
- •b) AST and ALT <3 X ULN
- •c) Albumin =3.0 g/dL or albumin =2 g/dL if the lower level is considered by the investigator to be due to nutritional depletion
- •10) Adequate renal function, defined as
- •a) Serum creatinine <1.5 mg/dL and/or creatinine clearance =65 mL/min
- •11) =18 years old
- •12) If subject is female, she is non-pregnant, non-lactating and of
- •a) Non-childbearing potential (defined as surgically sterile or one year post-menopausal)
- •b) Childbearing potential using adequate birth control and having a negative pregnancy test performed at Screening and again within 5 days of Dosing Day 1; adequate birth control measures are defined as hormonal, chemical or barrier methods or abstinence. Other birth control methods must receive Sponsor approval prior to subject enrollment
- •13) Capable of understanding and agreeing to fulfill the requirements of the protocol
- •14) Sign the IRB/EC approved consent form.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) History of anaphylaxis to planned CT contrast agent; subjects with history of minor, mild allergic reactions (eg hives, rash, pruritis) to planned CT contrast agent may be premedicated with prednisone or other medications per institutional standard of care
- •2) Prior esophageal stent insertion, laser or photodynamic therapy
- •3) Prior chest RT or major esophageal surgery
- •4) Any prior receipt of cytotoxic chemotherapeutic agents
- •5) Prior receipt of other cancer treatments (ie Chelation therapy), vaccines or biological response modifiers/growth factors (ie GM-CSF, IL-2) within the past 4 weeks. Note: hormonal therapies (eg tamoxifen, anastrozole) and topical agents (eg 5-FU, imiquimod) will be allowed; no washout period will be required for these agents.
- •6) Prior malignancy unless disease free for =3 years Note: basal cell/squamous carcinoma of the skin, in situ cervical or breast carcinoma, or superficial transitional cell bladder carcinoma will be allowed. In addition, subjects with history of low risk prostatic carcinoma (ie clinical stage 1 or 2a, Gleason score <6, and prostate-specific antigen (PSA) <10 ng/mL at diagnosis) will be allowed.
- •7) Significant currently active systemic diseases including uncontrolled diabetes, severe heart disease (New York Heart Association Class III or IV, see Section 13.4), uncontrolled hypertension, myocardial infarction within 3 months, severe bronchial obstruction, uncontrolled seizure disorder, peripheral neuropathy greater than CTCAE grade 1, or any disease requiring anticoagulant therapy
- •8) Allergies to any of the active or inactive components of OncoGel (ie allergies to degradable PLGA [poly(lactide-co-glycolide) sutures])
- •9) Receipt of an investigational drug or device within 30 days prior to signing informed consent
- •10) Any medical condition or other circumstance that, in the Investigator’s opinion, would prevent completion of the study, interfere with analysis of the study results, or potentially aversely affect subject safety.
- •11) Known esophageal varices
研究者
相似试验
进行中（未招募）
1 期
A randomized study of the efficacy and safety of OncoGel™ treatment as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation prior to surgery in subjects with localized or loco-regional esophageal cancerlocalized or loco-regional esophageal cancerMedDRA version: 9.1Level: LLTClassification code 10015362Term: Esophageal cancerEUCTR2007-005051-42-BEProtherics Salt Lake City, Inc124
招募中
不适用
A Study on the Efficacy of Opioid-Free Anesthesia in Pediatric Cardiac SurgeryAtrial septal defect and ventricular septal defectJPRN-UMIN000043809Okayama University Hospital40
招募中
Unknown
Prospective study of the efficacy and safety of outpatient cold snare polypectomy (CSP) for low atypical duodenal adenomaJPRN-UMIN000050197Keio University150
进行中（未招募）
不适用
A randomized, controlled trial of the effect of Osigraft when used in the treatment of displaced femoral neck fractures – a pilot studyDisplaced femoral neck fractures are classified as Garden III and IV according to the Garden classification system for femoral neck fractures.MedDRA version: 8.0Level: PTClassification code 10016450EUCTR2005-004149-33-GBStryker Biotech, LLC
已完成
不适用
Comparative evaluation of efficacy and safety of ophthalmic viscosurgical devices in phacoemulsificatioCataractISRCTN34957881All India Institute of Medical Sciences (AIIMS) (India)56